Femto Technologies Inc. Announces $17 Million Private Placement.
(TheNewswire)
ASHKELON, ISRAEL AND VANCOUVER,BRITISH COLUMBIA – FEBRUARY26, 2025 - TheNewswire - Femto Technologies Inc. (Nasdaq: FMTO )(“ Femto ” or the “ Company ”), a FemTechpioneer and the creator of Sensera , a feminine wellnessproduct, today announced that it has entered intodefinitive agreements with institutional investors for the purchaseand sale of approximately $17 million of Common Shares (also known asSubordinate Voting Shares under British Columbia securities law) andpre-funded and investor warrants at a price of $4.17 per CommonUnit.
The offering consisted of the sale of Common Units (orPre-Funded Units), each consisting of (i) one (1) Common Share orPre-Funded Warrant, (ii) 1 Series A Warrants to purchase one (1)Common Share per warrant and (iii) 1 Series B PIPE Common Warrants topurchase one (1) Common Share per warrant. The offering price perCommon Unit is $4.17 (or $4.16999 for each Pre-Funded Unit, which isequal to the offering price per Common Unit sold in the offering minusan exercise price of $0.00001 per Pre-Funded Warrant). The Pre-FundedWarrants will be immediately exercisable and may be exercised at anytime until exercised in full. For each Pre-Funded Unit sold in theoffering, the number of Common Units in the offering will be decreasedon a one-for-one basis. The initial exercise price of each Series ACommon Warrant is $5.21 per Common Share. The Series A Common Warrantsare exercisable immediately and expire 60 months after the initialissuance date. The number of securities issuable under the Series ACommon Warrant is subject to adjustment as described in more detail inthe report on Form 6-K filed in connection with the offering. Theinitial exercise price of each Series B Common Warrant is $12.51 perCommon Share or pursuant to an alternative cashless exercise option.The Series B Common Warrants are exercisable immediately and expire 30months after the initial issuance date. The number of securitiesissuable under the Series B Common Warrant is subject to adjustment asdescribed in more detail in the report on Form 6-K filed in connectionwith the offering.
Aggregate gross proceeds to the Company are expected tobe approximately $17 million. The transaction is expected to close onor about February 27, 2025, subject to the satisfaction of customaryclosing conditions. The Company expects to use the net proceeds fromthe offering, together with its existing cash, for general corporatepurposes and working capital.
Aegis Capital Corp. is acting asexclusive placement agent for the private placement. Louis A . Brilleman, P.C. is acting ascounsel to the Company. Kaufman & Canoles, P.C. is acting ascounsel to Aegis Capital Corp.
The securities described above are being sold in aprivate placement transaction not involving a public offering and havenot been registered under the Securities Act of 1933, as amended (the“Securities Act”), or applicable state securities laws.Accordingly, the securities may not be reoffered or resold in theUnited States except pursuant to an effective registration statementor an applicable exemption from the registration requirements of theSecurities Act and such applicable state securities laws. Thesecurities were offered only to accredited investors. Pursuant to aregistration rights agreement with the investors, the Company hasagreed to file one or more registration statements with the SECcovering the resale of the Common Shares and the Shares issuable uponexercise of the pre-funded warrants and warrants.
This news release shall not constitute an offer to sellor the solicitation of an offer to buy nor shall there be any sale ofthese securities in any state or jurisdiction in which such offer,solicitation or sale would be unlawful prior to registration orqualification under the securities laws of any such state orjurisdiction.
ABOUT SENSERA
Sensera is a feminine wellness device on a mission tobridge the gap between feminine pleasure and wellness, providing aholistic self-care experience that adapts to a woman’s changingneeds. Sensera utilizes Femto’s proprietary Smart Release System(SRS) technology, including machine learning and AI, to enhancefeminine wellness. Sensera is a CES Innovation Awards® 2025 Honoraryin the AI category.
For more information on Sensera, please visit www.senserawellness.com and followus on Instagram , , and .
ABOUT FEMTO TECHNOLOGIES, INC.
Femto Technologies Inc. (Nasdaq: FMTO), previouslyknown as BYND Cannasoft Enterprises Inc., is a public Femtech company,pioneering a transformative change in the sphere of female wellness.Its proprietary Smart Release System (SRS technology) is embedded inSensera, which has been named CES Innovation Awards® 2025 honoree inthe AI category. Femto’s SRS technology is driving its R&Dactivities and product manufacturing for a variety of Femtechproducts.
The devices described in this news release are conceptdevices that are in the first stage of development and will be subjectto testing, experiments and regulatory approvals and therefore thereis no certainty that they will eventually be marketed.
For more information, please visit www.femtocorp.comand on SEDAR+: www.sedarplus.ca
MEDIA CONTACT
For product demonstration andmedia
Samantha Breen
Opportunity PR (for Sensera)
+1 949.290.2834
COMPANY CONTACT
Gabi Kabazo
Chief Financial Officer
Tel: (604) 833-6820
e?mail: ir@femtocorp.com
Cautionary NoteRegarding Forward-Looking Statements
This news release includes certain statements that maybe deemed “forward-looking statements” within the meaning ofSection 27A of the U.S. Securities Act of 1933, as amended, andSection 21E of the U.S. Securities Exchange Act of 1934, as amendedand under Canadian securities laws. When used in this news release,the words “may”, “would”, “could”, “will”,“intend”, “plan”, “anticipate”, “believe”,“estimate”, “expect” and similar expressions are intended toidentify forward?looking statements. Such statements are subject tocertain risks and uncertainties, and actual circumstances, events orresults may differ materially from those projected in suchforward-looking statements.
Although the Company believes the expectationsexpressed in such forward-looking statements are based on reasonableassumptions, such statements are not guarantees of future performance,and actual events or developments may differ materially from those inforward-looking statements. Such forward-looking statementsnecessarily involve known and unknown risks and uncertainties, whichmay cause the Company’s actual performance and financial results infuture periods to differ materially from any projections of futureperformance or results expressed or implied by such forward-lookingstatements. Such statements reflect the Company's current views withrespect to future events and are subject to such risks anduncertainties. Many factors could cause actual results to differmaterially from the statements made, including future financialperformance, unanticipated regulatory requests and delays, finalpatents approval, timing of the Sensera pre-order and those factorsdiscussed in filings made by the company with the Canadian securitiesregulatory authorities, including (without limitation) in thecompany's management's discussion and analysis for the year endedDecember 31, 2023 and annual information form dated April 2, 2024,which are available under the company's profile at www.sedarplus.ca,and in the Company’s Annual Report on Form 20-F for the year thenended that was filed with the U.S. Securities and Exchange Commissionon April 3, 2024. Should one or more of these factors occur, or shouldassumptions underlying the forward-looking statements prove incorrect,actual results may vary materially from those described herein asintended, planned, anticipated, or expected. We do not intend and donot assume any obligation to update these forward?lookingstatements, except as required by law. Any such forward-lookingstatements represent management's estimates as of the date of thisnews release. While we may elect to update such forward-lookingstatements at some point in the future, we disclaim any obligation todo so, even if subsequent events cause our views to change.Shareholders are cautioned not to put undue reliance on suchforward?looking statements.
Copyright (c) 2025 TheNewswire - All rights reserved.
NASDAQ: BCAN
BCAN Trading
-7.77% G/L:
$4.20 Last:
38,423 Volume:
$4.30 Open:



